Paper37524331
Prevalence of SARS-CoV-2 Variants and Disease Outcome of COVID-19 Patients in the Amazonas Region of Peru.
Campos CJ and 7 others. Am J Trop Med Hyg, 2023. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Prevalence of SARS-CoV-2 Variants and Disease Outcome of COVID-19 Patients in the Amazonas Region of Peru. Papers, record 37524331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37524331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prevalence of SARS-CoV-2 Variants and Disease Outcome of COVID-19 Patients in the Amazonas Region of Peru.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| SARS-CoV-2 | Major topic |
| COVID-19 | Major topic |
| Humans | |
| Prevalence | |
| Peru |
Source PubMed
References6
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36417212 | Epidemiological Analysis of COVID-19 Cases in Native Amazonian Communities from Peru. | Epidemiologia (Basel) | 2021 | https://conductscience.org/library/papers/36417212 | PubMed |
| 2 | 35601074 | Clinical challenges of SARS-CoV-2 variants (Review). | Exp Ther Med | 2022 | https://conductscience.org/library/papers/35601074 | PubMed |
| 3 | 35172687 | Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines. | Hum Vaccin Immunother | 2022 | https://conductscience.org/library/papers/35172687 | PubMed |
| 4 | 34812432 | SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence. | Lancet Reg Health Am | 2022 | https://conductscience.org/library/papers/34812432 | PubMed |
| 5 | 34704780 | The Emergence of Sars-CoV-2 Variant Lambda (C.37) in South America. | Microbiol Spectr | 2021 | https://conductscience.org/library/papers/34704780 | PubMed |
| 6 | 32401345 | Genetic variants and source of introduction of SARS-CoV-2 in South America. | J Med Virol | 2020 | https://conductscience.org/library/papers/32401345 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42536660 | Integrating research and surveillance to mitigate zoonotic disease risk in indigenous communities: Insights from an expert group meeting in Amazonas, Peru. | PLoS Negl Trop Dis | 2026 | https://conductscience.org/library/papers/42536660 | PubMed |
| 40285001 | The Association Between the Ct Value of SARS-CoV-2 and the Risk of Death from COVID-19 in Amazonas, Peru, During the Circulation of the Lambda, Gamma, and Delta Variants. | Viruses | 2025 | https://conductscience.org/library/papers/40285001 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37524331
GET https://conductscience.org/api/papers/v1/37524331/authors